![Nataliya Agafonova](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 350 039 $ am 31.05.2026
Dr. Nataliya Agafonova is a Chief Medical Officer at Longeveron, Inc. Dr. Agafonova was previously employed as a Senior Medical Director by Bristol Myers Squibb Co. and a Senior Medical Director by Otsuka Pharmaceutical Development & Commercialization, Inc. She received her doctorate degree from Bogomolets National Medical University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.05.2026 | 453’419 ( 1.5% ) | 350 039 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LONGEVERON INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2023 |
| Unternehmen | Position | Ende |
|---|---|---|
Otsuka Pharmaceutical Development & Commercialization, Inc.
 Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2023 |
| BRISTOL-MYERS SQUIBB COMPANY | Technik-/Wissenschafts-/F&E-Leiter | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 4 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Development & Commercialization, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceutical products | Health Technology |
Bogomolets National Medical University
 Bogomolets National Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Longeveron, Inc.
 Longeveron, Inc. BiotechnologyHealth Technology Operates as a biotechnology company which develops cellular therapies for aging-related and life-threatening conditions | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
